Pathogenetic treatment with strontium ranelate in women with postmenopausal osteoporosis
The possibility of recovering the functional status is now considered as an integral part of the development of new treatment strategies for chronic diseases, including osteoporosis (OP). The possibility to optimize the treatment of OP, by exerting a more physiological effect on bone and simultaneou...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2010-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The possibility of recovering the functional status is now considered as an integral part of the development of new treatment strategies for chronic diseases, including osteoporosis (OP). The possibility to optimize the treatment of OP, by exerting a more physiological effect on bone and simultaneously reducing the increased bone resorption and formation, is highly urgent. The system of osteoprotegerin (OPG), receptor activator of nuclear factor-κ B and its ligand has been confirmed to play a central role in the regulation of bone metabolism. At the same time, there is strong evidence that OPG performs a key function in bone metabolism regulation, by suppressing the differentiation of osteoclasts (OC) and reducing their activity. The synthesis of OPG decreases with age in postmenopausal and glucocorticoid-induced OP. Thus, more effective bone protection needs to elevate the level of OPG, by stimulating its synthesis. Bivalos facilitates the replication of osteoblasts and the higher expression of OPG, resulting in a reduction in the differentiation and activity of OC. Thus, Bivalos positively uncouples the interrelated processes of bone metabolism. A combination of the bone-forming and antiresorptive effects of the agent leads to the recovery of bone balance in favor of bone formation. Strontium ranelate should be presently considered as a first-line safe and effective agent for the long-term treatment of women with postmenopausal OP. |
|---|---|
| ISSN: | 1996-7012 2310-158X |